公开(公告)号：US20240092773A1

公开(公告)日：2024-03-21

申请号：US17786387

申请日：2020-12-22

申请人： UCB Biopharma SRL

发明人： Timothy John NORMAN ,  Zhaoning ZHU ,  Selvaratnam SUGANTHAN ,  Konstantinos RAMPALAKO ,  James MADDEN ,  Jag Paul HEER ,  Richard Jeremy FRANKLIN ,  Rickki Lee CONNELLY ,  Thierry DEMAUDE ,  Gregory William HASLETT ,  Benedicte LALLEMAND ,  Nathaniel Julius Thomas MONCK ,  Julian Hugh ROWLEY ,  Giancarlo TRANI

IPC分类号： C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

CPC分类号： C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

摘要： The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20230303517A1

公开(公告)日：2023-09-28

申请号：US17786394

申请日：2020-12-22

申请人： UCB Biopharma SRL

发明人： Timothy John NORMAN ,  Douglas BYRNE ,  Julian Hugh ROWLEY ,  Giancarlo TRANI ,  Konstantinos RAMPALAKOS ,  Nathaniel Julius Thomas MONCK ,  Benedicte LALLEMAND ,  Gregory William HASLETT ,  Rickki Lee CONNELLY ,  Jag Paul HEER ,  James MADDEN ,  Oliver PHILPS ,  Selvaratnam SUGANTHAN ,  Zeshan YOUSUF ,  Richard John MEARS

IPC分类号： C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

CPC分类号： C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

摘要： The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.